Clinical trials are increasingly “offshored” to developing countries. Many participants in these trials can plausibly be regarded as victims of deep structural injustices, e.g. severe avoidable poverty and lack of access to healthcare. This chapter discusses whether patients who benefit from drugs developed among the global poor have any special responsibility to remedy their unjust circumstances. More precisely, it examines whether such a responsibility can be grounded in the fact that these patients are beneficiaries of injustice. Finding no justification for singling out this group, the author ends by exploring the idea that the responsibility to remedy structural injustice is a more widely shared one.